Hologic Receives Additional CE-Marked Claims for Aptima® Combo 2® Assay for Chlamydia Trachomatis and Neisseria Gonorrhoeae in Europe
--Assay Now Cleared for Throat and Rectal Specimens for Use on the Panther System--
MARLBOROUGH, Mass. (June 20, 2017) – Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® Combo 2® Assay for Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhoea)...
Jun 20, 2017
Hologic Announces FDA Clearance of Aptima® Assay to Detect Herpes Simplex Virus 1 & 2
-- Aptima HSV 1 & 2 Assay Now Available Alongside Women's Health, Virology Menu on the Fully Automated Panther System --
Hologic, Inc. (Nasdaq: HOLX) announced today that it has obtained FDA clearance to market the Aptima® Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther® system. The...
Jun 15, 2017
Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure® for Non-Invasive Body Contouring (Lipolysis) of Back, Inner and Outer Thighs
SculpSure Now Cleared to Treat Five Areas of the Body
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for Cynosure's non-invasive body contouring product, SculpSure, to...
Jun 7, 2017
FDA Approves Hologic's Genius™ 3D Mammography™ Exam as the Only Mammogram Superior for Women with Dense Breasts*
--Genius exam improves cancer detection and reduces recall rates for women of all ages and breast types, including the nearly 50 percent of women of breast cancer screening age who have dense breasts--
Hologic, Inc. (Nasdaq: HOLX) announced today that the Genius™ 3D Mammography™ exam is now the only mammogram that is FDA-approved as superior to standard 2D mammography for routine breast...
May 16, 2017
Charles J. Dockendorff Elected to Hologic Board of Directors
Hologic, Inc. (Nasdaq: HOLX) announced today that Charles J. Dockendorff has been elected to the Company's Board of Directors, effective immediately. Mr. Dockendorff also was appointed to the...